FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma

On February 5, 2021, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.